PrEP

Despite the rate of HIV infection in adolescents and young adults, a study found that PrEP awareness is limited.

A new report from PrEP4All Collaboration warned that current research efforts aimed at controlling the COVID-19 pandemic are missing an important area of research into PrEP.

Leronlimab has been granted 2 other Fast Track designations as a combination therapy with HAART for HIV and as a treatment for metastatic triple-negative breast cancer.

On April 24, the CDC published some considerations for clinical providers who are evaluating adolescents for treatment with PrEP.

The study sought to determine the role of HIV related medical mistrust, and willingness to use PrEP among black women in the United States.

Researchers may be able to isolate reservoir cells from patients using the CD127 protein, which would make it possible to study what allows the cells to silence and reactivate the virus .

Emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets, F/TAF (Descovy, Gilead) was just as effective as emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg F/TDF (Truvada).

Hydroxychloroquine and remdesivir have been caught up in the rush to develop an effective treatment for COVID-19.

A new study showed that most women living with HIV that were interviewed preferred long-acting injectable adherence to antiretroviral therapy over daily pills.

Implementation of adherence programs can be effective in improving outcomes for patients and reduce costs both at the patient and systemic level.

Widely used medications for patients with HIV/AIDS may be potential treatments for the coronavirus disease 2019 should the drugs demonstrate safety and efficacy in clinical trials.

The antiviral drug remdesivir has been shown by researchers to effectively stop the replication mechanism of SARS-CoV-2 that causes COVID-19, according to a new study.

Remdesivir is not yet licensed or approved anywhere internationally and has not been demonstrated to be safe or effective for the treatment of COVID-19.

The findings showed that non-SCD congenital anemia diagnosis was associated with a higher risk of HIV acquisition compared with SCD, according to the study authors.

The objective of the study was to determine whether there was an association between PrEP use and decreases in HIV diagnoses.

FDA updates guidelines after man who recently recovered from COVID-19 was told that he could not donate blood for 12 months because he takes Truvada as a pre-exposure prophylaxis treatment.

The antiviral drug remdesivir was originally developed as a treatment for Ebola in 2014, but upon the surge of COVID-19, its use was investigated in treating COVID-19.

More than one-third of transgender women (TGW) not living with HIV at baseline were indicated for pre-exposure prophylaxis (PrEP).

US Department of Health and Human Services (HHS) Secretary Alex Azar released a statement on how the authorization for pharmacists will mean easier access for patients who need COVID-19 testing.

As investigators continue to study the use of drugs such as remdesivir for the treatment of the COVID-19 pandemic, some researchers are considering drug repurposing as a temporary solution.

Pharmacists push against state-level limits on dispensing of hydroxychloroquine for coronavirus disease 2019.

The FDA has announced that it is accelerating the development of potentially safe and effective life-saving treatments for patients with the coronavirus 2019 disease.

The prevalence of HIV in jails and prisons is approximately 4 times higher than that of the general United States population.

Other therapeutic possibilities include a combination of HIV-1 protease inhibitors.

Researchers at the National Institutes of Health (NIH) have found that the antiretroviral drugs, dolutegravir and emtricitabine/tenofovir alafenamide fumurate (DTG+FTC/TAF), may comprise the safest and most effective HIV treatment regimen currently available during pregnancy.